Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma

  • Authors:
    • Kahori Seto
    • Junichi Shoda
    • Tomohisa Horibe
    • Eiji Warabi
    • Kazunori Ishige
    • Kenji Yamagata
    • Masayuki Kohno
    • Toru Yanagawa
    • Hiroki Bukawa
    • Koji Kawakami
  • View Affiliations

  • Published online on: April 4, 2013     https://doi.org/10.3892/or.2013.2387
  • Pages: 2147-2153
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Interleukin-4 receptor α (IL-4Rα) is highly expressed on the surface of various human solid tumors including head and neck squamous cell carcinoma (HNSCC). We designed a novel IL-4Rα-lytic hybrid peptide composed of a binding peptide to IL-4Rα and a cell-lytic peptide. In the present study, we evaluated the antitumor activity of the IL-4Rα-lytic hybrid peptide as a novel molecular-targeted therapy in HNSCC. Immunoblot analysis revealed that IL-4Rα was expressed in all tested HNSCC cell lines (HSC-2, HSC-3, HSC-4, Ca9-22 and OSC-19), but not in a human normal keratinocyte (HaCaT) cell line. Immunohistochemical expression levels of IL-4Rα in HNSCC tissues were higher compared to those in normal epithelial tissue. The IL-4Rα-lytic hybrid peptide showed cytotoxic activity in all five cancer cell lines with a concentration that killed 50% of all cells (IC50) as low as 10 µM. HaCaT cells were less sensitive to this peptide with an IC50 of >30 µM. In addition, intratumoral administration of IL-4Rα-lytic hybrid peptide significantly inhibited tumor growth in a xenograft model of human HNSCC in vivo. These results indicate that the IL-4Rα-lytic hybrid peptide may serve as a potent agent to provide a novel therapy for patients with HNSCC.
View Figures
View References

Related Articles

Journal Cover

June 2013
Volume 29 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Seto, K., Shoda, J., Horibe, T., Warabi, E., Ishige, K., Yamagata, K. ... Kawakami, K. (2013). Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma. Oncology Reports, 29, 2147-2153. https://doi.org/10.3892/or.2013.2387
MLA
Seto, K., Shoda, J., Horibe, T., Warabi, E., Ishige, K., Yamagata, K., Kohno, M., Yanagawa, T., Bukawa, H., Kawakami, K."Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma". Oncology Reports 29.6 (2013): 2147-2153.
Chicago
Seto, K., Shoda, J., Horibe, T., Warabi, E., Ishige, K., Yamagata, K., Kohno, M., Yanagawa, T., Bukawa, H., Kawakami, K."Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma". Oncology Reports 29, no. 6 (2013): 2147-2153. https://doi.org/10.3892/or.2013.2387